Apnimed Statistics
Total Valuation
Apnimed has a market cap or net worth of $645.28 million. The enterprise value is $562.86 million.
| Market Cap | 645.28M |
| Enterprise Value | 562.86M |
Important Dates
The next estimated earnings date is Tuesday, November 17, 2026, after market close.
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Apnimed has 41.63 million shares outstanding. The number of shares has increased by 562.85% in one year.
| Current Share Class | 41.63M |
| Shares Outstanding | 41.63M |
| Shares Change (YoY) | +562.85% |
| Shares Change (QoQ) | -24.89% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 22.91% |
| Float | 20.46M |
Valuation Ratios
The trailing PE ratio is 1.83.
| PE Ratio | 1.83 |
| Forward PE | n/a |
| PS Ratio | 5.57 |
| Forward PS | 1,282.23 |
| PB Ratio | 9.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 3.42 |
| EV / Sales | 4.85 |
| EV / EBITDA | 15.56 |
| EV / EBIT | 15.58 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.19, with a Debt / Equity ratio of 1.30.
| Current Ratio | 5.19 |
| Quick Ratio | 4.88 |
| Debt / Equity | 1.30 |
| Debt / EBITDA | 2.49 |
| Debt / FCF | n/a |
| Interest Coverage | 12.61 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 22.44% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $1.42M |
| Profits Per Employee | $2.02M |
| Employee Count | 81 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 22.48 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 33.76 |
| Average Volume (20 Days) | 381,340 |
Short Selling Information
The latest short interest is 1.80 million, so 4.33% of the outstanding shares have been sold short.
| Short Interest | 1.80M |
| Short Previous Month | 1.76M |
| Short % of Shares Out | 4.33% |
| Short % of Float | 8.82% |
| Short Ratio (days to cover) | 2.78 |
Income Statement
In the last 12 months, Apnimed had revenue of $115.12 million and earned $163.58 million in profits. Earnings per share was $8.49.
| Revenue | 115.12M |
| Gross Profit | 108.10M |
| Operating Income | 35.87M |
| Pretax Income | 170.74M |
| Net Income | 163.58M |
| EBITDA | 35.90M |
| EBIT | 35.87M |
| Earnings Per Share (EPS) | $8.49 |
Balance Sheet
The company has $172.80 million in cash and $90.39 million in debt, with a net cash position of $82.42 million or $1.98 per share.
| Cash & Cash Equivalents | 172.80M |
| Total Debt | 90.39M |
| Net Cash | 82.42M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 69.76M |
| Book Value Per Share | -36.69 |
| Working Capital | 149.19M |
Cash Flow
| Operating Cash Flow | -69.94M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 27,000 |
| Net Borrowing | 83.19M |
| Free Cash Flow | -69.94M |
| FCF Per Share | -$1.68 |
Margins
Gross margin is 93.90%, with operating and profit margins of 31.16% and 142.10%.
| Gross Margin | 93.90% |
| Operating Margin | 31.16% |
| Pretax Margin | 148.32% |
| Profit Margin | 142.10% |
| EBITDA Margin | 31.18% |
| EBIT Margin | 31.16% |
| FCF Margin | n/a |
Dividends & Yields
Apnimed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -562.85% |
| Shareholder Yield | -562.85% |
| Earnings Yield | 54.79% |
| FCF Yield | -10.91% |
Analyst Forecast
The average price target for Apnimed is $50.33, which is 224.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $50.33 |
| Price Target Difference | 224.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 55.46% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Apnimed has an Altman Z-Score of 0.65 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.65 |
| Piotroski F-Score | 1 |